TZOR

Chicago stops voters from deciding what matters. In fact, no other big city does more to discourage democratic participation in local government. Here are five examples. 1. The rule of three: Advisory questions can be useful. But in Chicago, they crowd out valuable ballot space. That’s because state law sets a “rule of three” in city elections, meaning only three referenda can appear at any one time. Lawmakers can use the rule of three to box out citizen-initiated referenda. So it’s no surprise Chicago voters haven’t decided a single issue on the ballot via citizen initiative in modern history. 2. Severely gerrymandered wards: Chicago politicians can pick their voters. Chicago City Council members, in concert with the mayor’s office, draw their own districts to reward friends and punish enemies. 3. February elections: Chicago is the only big city in the country that holds its municipal elections in February of an odd year. This timing suppresses voter turnout by 40%. 4. No city charter: Chicago is the only big city in the country without a charter. That means there is no mechanism nor civic culture for charter revision. Across the country, big-city charter revisions routinely offer voters the opportunity to decide serious governance matters. 5. Poor selection of elected offices: Chicagoans elect one citywide office that truly matters: the mayor. The other two citywide offices (clerk and treasurer) have very little authority. Unlike other big cities, Chicagoans do not elect an independent city attorney or chief financial officer. Go deeper in this week's edition of The Last Ward. thelastward.org/p/how-chicago-…

@A_May_MD @ezmoneymonty 100%, get the deal done and move on

For sure the current $ABVX stock performance is annoying. Actually I’d say it has been infuriating in light of the data they’ve presented. To be trading BELOW the pre-maintenance data that ultimately exceeded EVERYONE’S expectations is ridiculous, especially in an otherwise strong market. I’m sure much of the investor base feels the same way - annoyed, even angry (I’ll admit that I’m inching into the “angry” category myself). I’m sure that management is hearing about it from investors. However, I *do* think that this poor stock performance and resulting investor base displeasure may help bring the M&A timeline forward. In an alternate universe where we never had that stupid maintenance data hiccup and the stock is trading at $175 right now, investors are likely riding that high and less concerned about an M&A timeline, whether it’s before or after Crohns. But in reality we have a scenario where investors are furious for having taken a gamble on the data, getting the gamble RIGHT, and still somehow LOSING money on it anyway, PLUS the lost opportunity cost of what we could’ve done with this capital in a frothy market. In this scenario, I suspect the investor base is much more emphatic about a near term deal being done, and certainly the premium paid by big pharma would be much more palatable from these levels (a $210 deal would only be 20% premium on $175, but it would be >60% from here! Much easier sell for $ABVX, while still being easy to digest for big pharma). I know that at least *I* am supportive of a near term deal, especially from these ridiculous prices. And that’s coming from someone who has now said for over a full YEAR that the company should WAIT to sell itself. Not anymore. IMO it’s time to get moving. Point being - yes this stupid price action is infuriating. But I do think that it’s another legitimate tip in the scales weighing toward us getting what we want sooner…a near term deal.

World class hires by $ABVX. People who launched drugs like Entyvio, Humira, Rinvoq, Skyrizi, etc. They continue to poach absolute top tier talent for the next big drug in I&I. Side note: I can’t believe we have to constantly reiterate that $ABVX hiring a launch team is a GOOD thing. They can (and should) continue hiring for the potential launch right up until the very day they’ve signed a term sheet for a buyout. There’s truly only upside potential from building out a star studded team. The ONLY way they can lose leverage on this front is by failing to have launch infrastructure in place. The ROI is blatantly obviously upside skewed…build the team! We are talking about a potentially $20B price tag for this company…You’re braindead if you don’t realize that spending a few million dollars on new hires is about the strongest negotiating leverage that that kind of money can possible buy.

@InfoBreakout Sure, I’m watching. Not going to happen. I’d love to be wrong as I’d make more money being wrong.

@83lease Watch

$LLY buys out $NKTR

@A_May_MD Great call, excellent work, cheers to many more

Today is the 1 year anniversary of my $ABVX pitch. At $134 currently, that’s a 1,247% return from $9.95. It was my biggest position then, and it’s my biggest position now. I’d hazard a guess that an ending to the story is in sight. Let’s see!

@mikehunt492226 If I had a $ for every time I’ve heard about how they are looking for late stage assets, then go buy phase 1 asset, I’d have many $’s

BP is “looking for later-stage assets that are commercially ready,” said Ailsa Craig, fund manager at Schroders’ International Biotechnology Trust. “That makes sense since the intellectual property patent cliffs are around the corner, so they need the assets tomorrow” $ABVX

@AmateurBioturd @Duke0035 @Biotech2k1 Agreed, I certainly don’t have or claim to have alpha, but I can certainly spot that this guy doesn’t have alpha either. Said another way, his lack of alpha is showing.

@83lease @Duke0035 @Biotech2k1 Finding actual alpha on this app is indeed a challenge. I know I have none, and never claim to… I also assure you, this guy ain’t it lol.

This is my open post. I do not let people reply unless I follow them. That keeps out all the bots and scammers. If you want me to follow you so you can reply, just let me know.

@Duke0035 @Biotech2k1 It’s interesting at one point I thought he was a good resource of information then seeing this and he’s just slop.

@Biotech2k1 $ABVX Just a friendly reminder, this is the guy that thought obefazimod causes cancer.

NEW: Cook County inspector general report finds Commissioner Samantha Steele offered her primary opponent a job to drop out of the race, then lied to the media and refused to cooperate with investigators. She is directed to retake ethics training.

@WestLoopTom 😂

The air quality is so bad in Chicago that people are stopping in Richard’s just to get some fresh air.

@Duke0035 @SizeInvestor I’m at 2.7% of port for the readout next month

@SizeInvestor I think it's $TENX -> $ABVX How big are you sizing $TENX ? I'm pretty bullish, but not going too crazy.

I can't be the only one running a giant $ABVX position and praying for a buyout ASAP so that I can roll it into the $TENX binary. It's either called investment genius or tax management. And I'm pretty sure my wife will stay married to me either way.

Now that I sold some of my $ABVX calls, can we go higher now?

@DueDoctor Let’s go MDG, get it done

I don’t know who needs to hear this but $ABVX has already showed their cards 1. ATM was oversubscribed, essentially a sweet heart deal 2. Closed in one day (not standard) 3. The MGMT basically said they want to sell if price is right 4. If/when Crohns hits it essentially becomes too big to buy for most companies I don’t see a way forward unless it is a quick sale Reuters reported before latest data follow up multiple buyers The one holdback is - what price? This holdback is solved by one fact and one fact only Multiple bidders = FOMO Biotechs don’t sell, they get bought If you have Crohns hit it is a $10BN revenue It’s basically pay less now vs pay more later if you expect it to hit I absolutely expect one or more pharmas to bid heavily and see Crohns as a call option So what will Abivax MGMT do? You absolutely sell if you can get $220 or more a share For the sweetheart ATM that’s a 76% increase in short time There’s just too much at stake and a MGMT that imo does NOT want to launch a drug

@CloisterRes Would filing the NDA not be a catalyst, at least in the eyes of a would be buyer? Did MDG not say they were intent on filing the NDA by the end of July?

$ABVX really is in an odd spot. This thing should be up much more than it is. But there are no catalysts in the near term? But everyone knows it's going to get bought out in the near term? But buyout is getting pretty big number up here? But pharma buying multiple $10b companies?

@Paperboy2009 @A_May_MD @CloisterRes Agreed, the money would be tied up until expiration, which would be roughly a year and a half. I like the trade but wouldn’t want to tie my money up for that long.

@A_May_MD @CloisterRes ....that's a lot of capital and buying power to be tied up if it's going to be measured in months

@NegativeC16495 Keep this going until it looks like this

$CRNX is bullish for $ABVX $10B in potential new flows 2nd time’s the charm

@Taintslapp12283 Yup, it’s disgraceful, dare I say trash?

$ABVX the weakness is extraordinary. Up 13 dollars from pre data levels and people are happy. This is a disgrace.

@deathtouch2k Can we just add $4B to the market cap now? Asking for a friend

$ABVX Was told ~$4B of demand for the $600M raise

@BiotechTV @bradloncar Clarify the French regulations and how to balance that with the decision to raise vs engage with BP if one precludes the other?

$ABVX should be >$150 in no time. Frankly in this market it is easy to argue it should go even higher. Perfectly clean label (no black box). Greatest maintenance efficacy of all time (>2x ER rate of the former best drug). Greatest non-responder crossover efficacy of all time (this is huge for commercial uptake, because the induction study only treated patients for a very short 8 weeks. $ABVX just proved if you simply treat them longer, huge portions of patients end up responding. MASSIVE for long term revenue generation). This is a $5B+ peak sales drug in UC alone. Obefazimod will be used in the first line, the last line, and every line in between. Frankly I have never seen such a resoundingly positive/better than expectations P3 dataset readout in I&I ***ever***. Thanks to the temporary mass delusion that there was some cancer problem here, you can somehow still buy this at $117 for LESS than the $130 price tag it was trading at into data. Oh! And the $XBI is up almost 20% from the day that the first dataset was released!?! $ABVX would (theoretically) be >$150 just on tracking the biotech bull market the market alone, WITHOUT these blowout P3 data.....Just digest all of the above and you decide if that makes sense or how long this pricing should last. I personally see >$150 tomorrow making sense to me. My opinion is that this rerates rapidly the rest of the week to $150-$180, with a giant offering announced at some point. Then, I ultimately think the story (***IMO***) ends with a M&A on a 2-handle. Time for the funds to put in for their allocations in the offering! This one *should* be as hot as it gets in this raging bull market!